Cipla Health's Omnigel debuts first sub-brand Maxstrong in 2% diclofenac category
Omnigel launches Omnigel Maxstrong, entering the higher-strength 2% diclofenac pain-relief segment with a '5X Action' claim, premium packaging, and both gel and spray formats across sizes from 30gm to 100gm.
What happened
Cipla Health's pain relief brand Omnigel launches Omnigel Maxstrong, its first sub-brand, entering the 2% diclofenac category with new premium packaging and gel
Key facts
- 2% diclofenac
- 5X Action
- 30 gm
- 35 gm
- 55 gm
- 75 gm
- 100 gm
- 20 brands
Why this matters
The move to build a premium sub-brand organically rather than acquire indicates confidence in Omnigel's equity, but watch whether rival diclofenac players respond with M&A or aggressive launches in the 2% segment.
What to watch
- Competitor launches or claims in 2% diclofenac OTC tier
- Regulatory scrutiny on '5X Action' substantiation or Schedule H labeling
- Cannibalization ratio of base Omnigel volumes in first two quarters
- Pricing gap sustainability vs Volini/Moov premium SKUs
- Spray-format repeat-purchase rate as adoption signal
- Push modern-trade and pharmacy shelf placement adjacent to base Omnigel to anchor trade-up
- Run comparative efficacy messaging ('5X Action') across digital and doctor-detailing channels
- Introduce trial-size 30gm SKUs to lower switching friction for existing users
- Monitor and lock distributor margins on spray format as the differentiator vs gel-only rivals